Prospects for Reducing Gastrotoxicity of Anti-Inflammatory and Analgesic Therapy While Using Amtolmetin Guacil

Konshina T. M.
MD, PhD, Assistant Professor, Chair for Pharmacology¹²

Goldobina G. V.
MD, PhD, Assistant Professor, Chair for Pharmacology¹

Bolotskaya N. V.
MD, PhD, Assistant Professor, Chair for Pharmacology¹

Burlutskaya A. A.
Lecturer, Chair for Pharmacology¹

Khorinko V. P.
MD, PhD, Lecturer in Gistology, Medical and Pharmaceutical School¹

Konshina Y. A.
Subordinator¹

1 - E.A. Vagner Perm State Medical University, Perm, Russia
2 - Perm State Pharmaceutical Academy, Perm, Russia

Tatiana Michaylovna Konshina; e-mail: tmkpharm@mail.ru

None declared.

The study had no sponsorship.

The most important problem of non-steroid anti-inflammatory drugs (NSAIDs) is a high risk of ulcerogenicity. It is possible to reduce it by the increase in gastric mucosa concentrations of gastroprotective NO. New NSAIDs Amtolmetin guacil (AMG) was registered in Russia in 2013. It is positioned as an effective medicine with gastroprotective action. AMG stimulates capsaicinoid receptors and accumulates NO in the stomach. However, the data on the effectiveness and safety of AMG are few. During its metabolism highly ulcerogenic Tolmetin is formed. The purpose of our research was to study the anti-inflammatory, analgesic and ulcerogenic effect of AMG after intragastric administration. The research was carried out on white nonlinear mice and rats of both sexes. Our study showed that AMG effectively reduced the severity of carrageenan edema of the rat's paw and reduced the number of acetic cramps in mice. Gastric mucosa of most animals was without pathological changes, single shallow erosions without infiltration were found in 32% of animals after administration during 4 days of AMG to rats at a dose of 200 mg/kg once a day. Diclofenac in the same conditions at a dose of 10 mg/kg caused deep defects in 75% of rats. AMG showed pronounced analgesic and anti-inflammatory effect. Our results also confirmed the advantage of AMG compared to diclofenac in its effect on the gastric mucosa.

non-steroidal anti-inflammatory drugs, amtolmetin guacil, ulcerogenicity, gastrotoxicity, diclofenac

10.29234/2308-9113-2020-8-4-13-24

1. Argunova I.A. Splav komorbidnosti i polipragmazii kak risk ul'cerogeneza. Vozmozhnosti prognozirovaniya i profilaktiki simptomaticheskih gastroduodenal'nyh yazv. [Comorbidity plus polypharmacy as risk of ulcerogenesis. Possibilities for prediction and prevention of symptomatic gastroduodenal ulcers]. Poliklinika [Polyclinic] 2016; (4-3): 44-49. (In Russ.)

2. Vyalov S.S. Protivovospalitel'naya terapiya i gastrotoksichnost': real'nye vozmozhnosti profilaktiki. [Anti-Inflammatory therapy and gastrotoxicity: real possibilities of prevention]. RMZH [RMJ] 2014; (22):1644-1649. (In Russ.)

3. Gajdukova I.Z., Rebrov A.P., Hondkaryan H.V., Aparkina A.V. Effektivnost' i kardiovaskulyarnaya bezopasnost' amtolmetinguacila v lechenii bol'nyh ankiloziruyushchim spondilitom (bolezn' Bekhtereva): Okonchatel'nye rezul'taty issledovaniya CORONA. [Efficacy and cardiovascular safety of amtolmetin guacil in the treatment of patients with ankylosing spondylitis: final results of CORONA study]. Farmateka [Pharmateca] 2016; 7 (320): 53-58. (In Russ.)

4. Gajdukova I.Z., Haparkina A.V., Rebrov A.P. Izmenenie koncentracii molekul adgezii i faktora rosta ehndoteliya sosudov v syvorotke krovi pri primenenii amtolmetinaguacila u pacientov s aktivnym ankiloziruyushchim spondilitom: rezul'taty 56-nedel'nogo prospektivnogo otkrytogo kontroliruemogo nablyudeniya. [Changes in the concentration of adhesion molecules and vascular endothelial growth factor in blood serum in patients with active ankylosing spondylitis using amtolmetinguacil: results of 56-week prospective open controlled follow-up]. Terapevticheskij arhiv [Therapeutic archive] 2017; 89 (5): 38-45. (In Russ.)

5. Gajdukova I.Z., Hondkaryan Eh.V., Aparkina A.V., Rebrov A.P. Sravnitel'naya ehffektivnost' i bezopasnost' trekh rezhimov naznacheniya nesteroidnyh protivovospalitel'nyh preparatov dlya lecheniya hronicheskoj boli v spine. [Comparative efficacy and safety of three modes for use of nonsteroid anti-inflammatory drugs for the treatment of chronic back pain]. Farmateka [Pharmateca] 2017; 7 (340): 34-39. (In Russ.)

6. Denisov L.N., Cvetkova E.S., Otteva Eh.N., Dubikov A.N., Yakupova S.P., Ivanova O.N., Korshunov N.I., Vajsberg A.R., Abyshev R.A., Tartynov A.V., Nasonov E.L. Ehffektivnost' i bezopasnost' amtolmetinaguacila v terapii osteoartrita i associirovannoj dispepsii v rutinnoj klinicheskoj praktike – «AGATA».[Efficacy and safety of amtolmetin guacil in the therapy of osteoarthritis and associated dyspepsia in routine clinical practice – AGATA]. Medicinskij sovet [Medical Council] 2018;(9): 56-60. doi: 10.21518/2079-701X-2018-9-56-60. (In Russ.)

7. Buzlama A.V Doklinicheskie issledovaniya lekarstvennyh veshchestv: uchebnoe posobie. [Preclinical studies of drugs: textbook]. Edited by Svistunov A.A. Moscow: GEHOTAR-Media, 2017. (In Russ.)

8. Drozdov V.N. NPVP s sobstvennym mekhanizmom zashchity zheludka – real'no li ehto? [NSAIDs with their own mechanism of protection of the stomach – is it real?]. RMZH [RMJ] 2013; (30): 1596-1599. (In Russ.)

9. Eliseev M.S., Zhelyabina O.V. Sochetanie podagry i bolezni deponirovaniya pirofosfatov kal'ciya: trudnosti diagnostiki i lecheniya. [The combination of gout and calcium pyrophosphate deposition disease: the difficulties of diagnosis and treatment]. RMZH. Medicinskoe obozrenie [RMJ. Medical Review] 2017; (1): 44-47. (In Russ.)

10. Karateev A.E. Amtolmetinguacil: mozhno li sozdat' «uluchshennyj» NPVP? [Amtolmetin guacil: is it possible to develop an «advanced» NSAID?]. Meditsinskiy Sovet. Revmatologiya [Medical Council. Rheumatology] 2013; (12): 84-89. doi: 10.21518/2079-701X-2013-12-84-89. (In Russ.)

11. Karateev A.E. Modifikaciya tradicionnyh NPVPkak metod povysheniya ih bezopasnosti i udobstva primeneniya. [Modification of traditional NSAIDs as a method of improving their safety and ease of use]. RMZH [RMJ] 2015; (7): 392-396. (In Russ.)

12. Kolokolov O.V., Kolokolova A.M. Bol' v spine u pacientov s komorbidnoj patologiej: kak vybrat' nesteroidnyj protivovospalitel'nyj preparat. [Back pain in comorbid patients: the choice of non-steroidal anti-inflammatory drug]. RMZH [RMJ] 2016; (25):1718-1723. (In Russ.)

13. Korucci G., Bertachini D. Vozdejstvie na zheludok novogo nesteroidnogo protivovospalitel'nogo lekarstvennogo preparata amtolmetinguacila. [The effect of the new non-steroidal anti-inflammatory drug amtolmetin guacil on the stomach]. RMZH [RMJ] 2013; (34): 1758-1764. (In Russ.)

14. Lapina T.L. Puti snizheniya gastrointestinal'nogo riska pri naznachenii nesteroidnyh protivovospalitel'nyh preparatov. [Ways to reduce gastrointestinal risk in the appointment of non-steroidal anti-inflammatory drugs]. Nevrologiya i revmatologiya. Prilozhenie Consilium medicum. [Neurology and rheumatology. Supplement to Consilium Medicum] 2013; (2): 9-11 (In Russ.)

15. Maksimov M.L. Vozmozhnosti snizheniya riska zheludochno-kishechnyh oslozhnenij pri lechenii sovremennymi nesteroidnymi protivovospalitel'nymi preparatami. [Possibilities for risk reduction of gastrointestinal complications in the course of the treatment with modern non-steroidal anti-inflammatory drugs]. RMZH [RMJ] 2016; (24):1643-1649. (In Russ.)

16. Pasechnikov V.D. Mekhanizmy zashchity slizistoj obolochki zheludka i NO-vysvobozhdayushchie nesteroidnye protivovospalitel'nye preparaty. [Mechanisms of protection of gastric mucosa and NO-releasing nonsteroidal anti-inflammatory drugs]. Consilium medicum 2013; 15 (9): 76-80. (In Russ.)

17. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. [Guidelines for Pre-clinical Trials of Drugs.] Edited by Mironov A.N. Moscow: Grif i K, 2012. (In Russ.)

18. Tavella A., Ursini D. Klinicheskoe issledovanie protivovospalitel'noj aktivnosti i perenosimosti so storony zheludochno-kishechnogo trakta Amtolmetinaguacila (novogo NPVP) po sravneniyu s diklofenakom u pacientov pozhilogo vozrasta s patologiyami kostno-sustavnoj sistemy. [Clinical study anti-inflammatory activity and tolerability from the gastrointestinal tract of Amtolmetinaguacil (a new NSAID) compared with Diclofenac in patients of advanced age with the pathologies of the osteoarticular system]. RMZH [RMJ] 2013; (32): 1678-1682. (In Russ.)

19. Trukhan D.I., Degovtsov E.N., Vybor NPVS dlya pacienta s hronicheskim posleoperacionnym bolevym sindromom na ambulatorno-poliklinicheskom ehtape: v fokuse – amtolmetinguacil. [Choice of NSAIDs for patients with chronic post-surgical pain on an outpatient-polyclinic stage: focus on amtolmetin guacil]. Stacionarozameshchayushchie tekhnologii: Ambulatornaya hirurgiya: [Ambulatory surgery: hospital-replacing technologies] 2016; (1-2): 88-93. (In Russ.)

20. Cvetkova E.S., Denisov L.N., Otteva Eh.N., Dubikov A.N., Yakupova S.P., Ivanova O.N., Korshunov N.I., Vajsberg A.R., Abyshev R.A., Tartynov A.V., Nasonov E.L. Otkrytoe mnogocentrovoe nablyudatel'noe issledovanie ehffektivnosti, perenosimosti i bezopasnosti nesteroidnogo protivovospalitel'nogo preparata amtolmetinaguacila u pacientov s osteoartritom kolennyh sustavov i dispepsiej. [An open-label multicenter observational study of the efficacy, tolerability, and safety of the nonsteroidal anti-inflammatory drug amtolmetin guacil in patients with knee osteoarthritis and dyspepsia]. Nauchno-prakticheskaya revmatologiya [Rheumatology Science and Practice] 2016; 54 (6): 654-659. (In Russ.)

21. Cimmerman Ya.S. Porazhenie zheludka, inducirovannoe priemom nesteroidnyh protivovospalitel'nyh preparatov (NPVP): NPVP-gastrit ili NPVP-gastropatiya? [Stomach damage induced by nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs-gastritis or NSAIDs-gastropathy?]. Klinicheskaya farmakologiya i terapiya [Clinical pharmacology and therapy] 2018, 27 (1): 14-21. (In Russ.)

22. Cukanov V., Vasyutin A., Tonkih Yu., Peretyat'ko O. Rasprostranennost' i faktory riska yazvennoj bolezni. [The prevalence and risk factors of peptic ulcer disease] Vrach 2018; 29 (12): 63-65. doi: 10.29296/25877305-2018-12-15. (In Russ.)